Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
However, Semaglutide has a longer track record of clinical validation, extensive cardiovascular outcome data (SUSTAIN-6 trial), and remains the foundational baseline against which all newer incretins are compared
GLP-1 receptor agonists, including exenatide, liraglutide, tirzepatide and semaglutide, mimic the action of GLP-1 and have been approved by the Food and Drug Administration to treat Type 2 diabetes and obesity
Oral Wegovy is engineered to mimic GLP-1, a natural hormone produced after meals
In November 2025, Novo Nordisk reduced Wegovys direct-to-consumer cash price to $349/month and announced a 50% list price cut effective January 2027
US$ 24.48
US$ 27.18
US$ 20.94
US$ 26.21
